Document is current

Article History

Received: 10 April 2023

Accepted: 31 May 2023

First Online: 7 June 2023

Declarations

:

: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of IRCCS Istituto Auxologico Italiano (code 2021_05_18_04).

: Informed consent was obtained from all subjects involved in the study.

: A.P. is an employee of Fujirebio Europe N.V. and provided technical assistance for plasma Aβ measurement; Fujirebio Europe N.V. did not influence to any extent analysis and interpretation of data. B.P. received compensation for consulting services and/or speaking activities from Liquidweb S.r.l. She is an Associate Editor for <i>Frontiers in Neuroscience</i>. N.T. received compensation for consulting services from Amylyx Pharmaceuticals and Zambon Biotech SA. He is an Associate Editor for <i>Frontiers in Aging Neuroscience</i>. V.S. received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb S.r.l., Novartis Pharma AG, and Zambon, and receives or has received research support from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. He is a member of the Editorial Boards of <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i>, <i>European Neurology</i>, <i>American Journal of Neurodegenerative Disease</i>, <i>Frontiers in Neurology</i>, and <i>Exploration of Neuroprotective Therapy</i>. The other authors have no relevant competing interests.